表紙
市場調查報告書
商品編碼
1067677

糖尿病管理技術:市場、參與者和預測 2022-2032年

Diabetes Management Technologies 2022-2032: Markets, Players, and Forecasts

出版日期: | 出版商: IDTechEx Ltd. | 英文 352 Slides | 商品交期: 最快1-2個工作天內

價格
  • 全貌
  • 簡介
  • 目錄
簡介

標題
2022-2032 年糖尿病管理技術:市場、參與者和預測
電化學血糖試紙、連續血糖監測儀 (CGM),包括無創、胰島素泵和筆、閉環、人工胰腺、數字健康。 2010-2032年糖尿病管理設備市場分析與預測。

到 2032 年,糖尿病管理技術的總市場規模預計將達到 289 億美元。

本報告涵蓋了糖尿病管理設備的整個前景,包括成熟的、新興的和未來的選擇。我們描述並預測未來十年該行業的技術格局。討論和分析了行業主要參與者的策略。我們的預測中會考慮和討論重大里程碑的發展,例如閉環系統和非侵入性 CGM 的推出。

在過去十年中,糖尿病管理設備行業發生了重大變化。中心是從電化學測試條向微創連續血糖監測儀 (CGM) 的轉變。價值數十億美元的試紙行業自 2010 年以來一直在下滑,而 CGM 僅繼續增長。 IDTechEx 預測,到 2032 年,試紙行業僅佔整個糖尿病管理設備市場的 6.7%,低於 2010 年 63.4% 的峰值。

葡萄糖傳感器:過去、現在和未來

糖尿病患者歷來使用一次性試紙來監測血糖,基於試紙的高利潤率創造了一個價值 74 億美元的行業。然而,定價壓力和更嚴格的報銷政策一直在推動試紙行業在 2010 年至 2015 年期間出現下滑。在歐盟,試紙面臨著自 2015 年以來增加 CGM 報銷的額外壓力。這些因素共同見證了試紙行業的前任領導者剝離行業剝離其糖尿病部門:拜耳醫療保健於 2016 年將其糖尿病護理業務出售給松下,2017 年強生將其 Lifescan 部門出售給 Platinum Equity。

另一方面,CGM 市場在過去幾年中快速增長。 IDTechEx 估計,2010 年至 2021 年間,整個 CGM 行業的複合年增長率超過 25%,主要由三大參與者推動:雅培、美敦力和 Dexcom。

CGM 市場規模和主要參與者的份額,2010-2021 年。

隨著 CGM 繼續受到重視,CGM 的增長和試紙的下降預計將繼續,但仍有幾個新興市場試紙正在擴張,這將減緩它們的下降速度。在本報告中,我們討論了試紙和CGM 行業向前發展的前景,提供了 CGM 和試紙的地理市場滲透率,以及未來 10 年試紙和 CGM 行業的市場預測年。

雖然 CGM 已經比試紙提供了相當大的優勢,但仍有很大的創新空間。這些設備仍然會引起不適和刺激,而 CGM 測量的時間滯後是它們所採用的機制的一個特徵缺陷。

數字健康:將 CGM 擴展到 2 型糖尿病

如今,由於需要嚴格控制血糖水平,葡萄糖傳感器行業為 1 型糖尿病患者提供服務。然而,這只是所有糖尿病患者的一小部分,僅佔總數的 5% 左右。因此,許多參與者現在正在推動 2 型和前驅糖尿病人群採用設備,因為這些都是尚未開發的大型市場。這是通過增加葡萄糖傳感器與數字健康選項的集成來實現的,主要的葡萄糖監測參與者希望與數字健康公司建立合作夥伴關係,以擴大產品供應。

糖尿病管理行業的創新遵循了連接性增加的趨勢。這已經在智能胰島素筆和連接血糖儀的開發中看到,在許多其他例子中。雖然這些都在最近的數字健康計劃發展中發揮了作用,但 CGM 一直是數字健康的主要推動力。

CGM 與數字健康平台的合作引起了雙方的極大興趣。由於提供了這種改進的數據,CGM 數據可以擴展數字健康平台的產品供應:許多具有 CGM 配對的糖尿病健康管理應用程序為用戶提供某種形式的 "糖尿病日記" 來跟蹤他們的血糖,並在頂部添加了功能這個數據。在 CGM 方面,數字健康提供了擴展到尚未開發的大型 2 型和前驅糖尿病市場的潛力。 CGM 巨頭 Dexcom 是這方面最突出的例子,除了在 2017 年與主要遠程醫療平台 Glooko 達成擴大合作協議外,還與許多小型應用平台合作。

胰島素輸送:邁向閉環的進展

胰島素輸送是糖尿病管理的關鍵部分。目前,這主要是通過胰島素筆完成的;這些設備在數量上構成了胰島素輸送市場的大部分,因為它們的低單位成本使消費者可以使用它們。

CGM 使開發自動化( "閉環" )胰島素輸送系統成為可能,這可能會促進胰島素泵市場的增長。這將使整個胰島素輸送行業發生重大轉變,對胰島素筆市場產生特別大的影響。在本報告中,我們討論了這些可能性的發展和時間表,並分析和預測了未來十年這將對胰島素輸送行業產生的影響。

2021 年主要參與者的胰島素泵市場份額。

糖尿病管理設備市場分析與預測

上面討論的行業是高度相互關聯的;一個行業的發展會對其他行業產生重大影響。 IDTechEx 分析了整個市場以產生一個有凝聚力的故事,將糖尿病管理行業的發展和未來里程碑聯繫在一起,為每個單獨的市場提供現實的預測。

雖然 CGM 一直是該行業的主要焦點,但整個行業都發生了許多值得注意的創新。在過去的幾年裡,許多新的參與者進入了多個行業的糖尿病管理技術市場。本報告討論了整個行業許多主題的市場潛力。

本報告分析了技術和競爭格局,確定並審查了從行業領導者到初創企業的 100 多家公司和研究機構。它確定了每個行業的關鍵參與者以及跨多個行業的合作夥伴生態系統。

本報告中討論的關鍵主題:

  • 試紙行業的發展前景
  • CGM 在中短期內滲透到亞洲市場
  • 進入 CGM 市場的障礙
  • 糖尿病管理中數字健康選項的展望
  • 胰島素輸送行業的趨勢和前景
  • 閉環對整個行業的時間表和影響
  • 併發症管理技術的發展與展望
  • 開髮用於逆轉糖尿病的先進療法

來自 IDTechEx 的分析師訪問權限

所有報告購買都包括最多 30 分鐘的電話時間,專家分析師將幫助您將報告中的主要發現與您正在解決的業務問題聯繫起來。這需要在購買報告後三個月內使用。

目錄

1。執行摘要

  • 1.1.高管介紹
  • 1.2.背景:糖尿病簡介
  • 1.3.背景:糖尿病的成本
  • 1.4.糖尿病管理流程
  • 1.5。報告範圍
  • 1.6.糖尿病管理設備路線圖:葡萄糖傳感器
  • 1.7.試紙和血糖儀:簡介
  • 1.8.葡萄糖試紙的解剖
  • 1.9.連續血糖監測儀:簡介
  • 1.10。典型 CGM 設備的剖析
  • 1.11。 CGM繼續獲得動力
  • 1.12。無創血糖監測
  • 1.13。無創血糖監測:結論
  • 1.14.糖尿病管理設備路線圖:胰島素輸送
  • 1.15。胰島素筆:概述
  • 1.16。胰島素泵:概述
  • 1.17.混合閉環:介紹
  • 1.18.胰島素輸送行業的現狀取決於閉環系統的發展
  • 1.19。替代胰島素輸送方法尚未站穩腳跟
  • 1.20。數字健康是由增加的設備連接性驅動的
  • 1.21。數字健康是糖尿病管理的一個日益增長的選擇
  • 1.22。管理副作用佔糖尿病總成本的 90%
  • 1.23。糖尿病併發症管理展望
  • 1.24。糖尿病的先進療法:路線圖
  • 1.25。先進療法:結論
  • 1.26。本報告提及的108家公司名單
  • 1.27。糖尿病管理設備:2010-2021 年收入
  • 1.28。 2010-2032年整體糖尿病器械行業評價
  • 1.29。 CGM:2022-2032年年度收入預測
  • 1.30。 2022-2032年試紙市場預測
  • 1.31。 2022-2032 年胰島素泵收入預測

2。簡介

  • 2.1.背景:糖尿病簡介
  • 2.2.糖尿病患病率
  • 2.3.背景:糖尿病呈上升趨勢
  • 2.4.背景:糖尿病的成本
  • 2.5.類型 1 與類型 2
  • 2.6.背景
  • 2.7.自我管理設備
  • 2.8.糖尿病管理設備路線圖:摘要
  • 2.9.糖尿病管理設備路線圖:葡萄糖傳感器
  • 2.10。糖尿病管理設備路線圖:胰島素輸送

3。葡萄糖傳感器

  • 3.1.1.血糖監測歷史
  • 3.1.2.血糖監測的參與者
  • 3.1.3.糖尿病管理設備路線圖:葡萄糖傳感器
  • 3.1.4.評估準確性的關鍵標準
  • 3.2.試紙和血糖儀
    • 3.2.1.通過試紙和相關閱讀器進行血糖監測
    • 3.2.2.試紙:商業模式
    • 3.2.3.葡萄糖試紙的解剖
    • 3.2.4.電極沉積:絲網印刷與濺射
    • 3.2.5。 Lifescan 使用多種製造方法
    • 3.2.6.葡萄糖傳感簡介:葡萄糖氧化□
    • 3.2.7.通過 GOx 檢測葡萄糖:機制
    • 3.2.8.葡萄糖脫氫□:簡介
    • 3.2.9.葡萄糖脫氫□:傳感方法
    • 3.2.10。 GDH 和 GOx 機制的比較
    • 3.2.11。 GDH-FAD具備發展 "第三代" 傳感器的潛力
    • 3.2.12。 GDH 和 GOx 在葡萄糖傳感中的比較
    • 3.2.13。使用的幾種試紙和□概述
    • 3.2.14.羅氏:概述
    • 3.2.15。羅氏:Accu-Chek 指南
    • 3.2.16. Roche/Glytec:cobas Pulse
    • 3.2.17.雅培實驗室:簡介
    • 3.2.18.雅培:用於試紙的庫侖法
    • 3.2.19. EasyMax 糖尿病護理
    • 3.2.20。創新從試紙開發轉向數字化
    • 3.2.21。將試紙成本與 CGM 進行比較
    • 3.2.22。試紙:市場前景
  • 3.3.連續血糖監測 (CGM)
    • 3.3.1.連續血糖監測儀:簡介
    • 3.3.2.典型 CGM 設備的剖析
    • 3.3.3. CGM 正在取代試紙
    • 3.3.4. CGM:技術
    • 3.3.5。 CGM 傳感器化學
    • 3.3.6. CGM 技術:葡萄糖脫氫□
    • 3.3.7. CGM小型化與 "綠色" 糖尿病
    • 3.3.8. CGM 傳感器製造和解剖學
    • 3.3.9.傳感器燈絲結構
    • 3.3.10。對 CGM 設備的異物反應
    • 3.3.11。葡萄糖監測設備的校準
    • 3.3.12。 CGM 設備的比較指標
    • 3.3.13。示例:CGM 設備隨時間推移的準確性
    • 3.3.14.藥物對 CGM 準確性的干擾
  • 3.4. CGM:市場和主要參與者
    • 3.4.1. CGM:主要參與者概述
    • 3.4.2.雅培實驗室:CGM 業務
    • 3.4.3.雅培:自由式®自由
    • 3.4.4.雅培: "有線□"
    • 3.4.5。雅培:設備和傳感器結構
    • 3.4.6. Dexcom:簡介
    • 3.4.7. Dexcom:CGM 產品
    • 3.4.8. Dexcom:傳感器結構
    • 3.4.9.美敦力:簡介
    • 3.4.10。美敦力:糖尿病和 CGM 業務
    • 3.4.11。羅氏:CGM 中的專利
    • 3.4.12。 Ascensia、POCTech 和 Yuwell
    • 3.4.13。美敦力
    • 3.4.14。 Medtrum:傳感技術
    • 3.4.15。 Medtrum:展望
    • 3.4.16。 AgaMatrix & WaveForm 技術
    • 3.4.17.英菲諾沃
    • 3.4.18。佐野
  • 3.5.植入式葡萄糖傳感器
    • 3.5.1.植入式葡萄糖傳感器:簡介
    • 3.5.2.植入式血糖監測的主要參與者
    • 3.5.3.基於螢光的葡萄糖檢測
    • 3.5.4.感官學
    • 3.5.5。 Senseonics:財務和合作夥伴關係
    • 3.5.6. GlySens:日食 3
    • 3.5.7. GluSense
  • 3.6. CGM:結論
    • 3.6.1.焦點從試紙轉移到 CGM
    • 3.6.2.全球CGM報銷
    • 3.6.3.亞洲 CGM 市場
    • 3.6.4.小型試紙公司的前景
    • 3.6.5。類型 2 的 CGM 報銷目前是有限的
    • 3.6.6. CGM 在醫院的使用
  • 3.7.無創血糖監測
    • 3.7.1.無創血糖監測
    • 3.7.2.評估用於血糖監測的不同分析物
    • 3.7.3.背景:FDA 要求
    • 3.7.4.非侵入性血液和 ISF
    • 3.7.5。無創血糖監測:方法
    • 3.7.6.使用每種技術的公司
    • 3.7.7.近紅外光譜
    • 3.7.8.近紅外光譜 - 最近的學術研究
    • 3.7.9.近紅外公司
    • 3.7.10。 CNOGA
    • 3.7.11。中紅外光譜
    • 3.7.12。米爾公司
    • 3.7.13。鑽石科技
    • 3.7.14。太赫茲光譜
    • 3.7.15。介電光譜
    • 3.7.16。警覺
    • 3.7.17。知道實驗室
    • 3.7.18。雅方科技
    • 3.7.19。澤森
    • 3.7.20。澤森
    • 3.7.21。拉曼光譜
    • 3.7.22。 Kaligia 生物科學
    • 3.7.23。量子操作
    • 3.7.24。 RSP 系統
    • 3.7.25。三星
    • 3.7.26。旋光度
    • 3.7.27。透皮技術
    • 3.7.28。反向離子電滲療法
    • 3.7.29。反向離子導入公司
    • 3.7.30。根浦醫療
    • 3.7.31。 PK活力
    • 3.7.32。天鵝座
  • 3.8.無創血糖監測:其他液體
    • 3.8.1.使用每種技術的公司(其他流體)
    • 3.8.2.測量汗液中的葡萄糖
    • 3.8.3.測量眼淚中的葡萄糖
    • 3.8.4.測量唾液中的葡萄糖
    • 3.8.5.測量呼吸中的葡萄糖
    • 3.8.6.測量尿液中的葡萄糖
  • 3.9.無創血糖監測:結論
    • 3.9.1.無創血糖監測何時商業化?
    • 3.9.2.關於無創血糖監測的著名引述

4。胰島素輸送

  • 4.1.1.胰島素:介紹
  • 4.1.2.提供胰島素是糖尿病管理的關鍵部分
  • 4.1.3.不同類型胰島素的比較*
  • 4.1.4.短效(推注)胰島素
  • 4.1.5。長效(基礎)胰島素
  • 4.1.6.不同類型的胰島素有不同的用例
  • 4.1.7.胰島素輸送裝置
  • 4.1.8.胰島素輸送方法的歷史
  • 4.1.9.來自兩個不同視角的技術路線圖
  • 4.2.胰島素筆
    • 4.2.1.胰島素筆
    • 4.2.2.更智能的胰島素輸送為決策提供信息
    • 4.2.3.智能筆受到不斷增長的 CGM 市場的推動
    • 4.2.4.智能胰島素筆的合作生態系統
    • 4.2.5。商用智能筆設備概述*
    • 4.2.6.諾和諾德
    • 4.2.7.諾和諾德:NovoPen
    • 4.2.8.禮來公司
    • 4.2.9.禮來公司:Tempo Smart
    • 4.2.10。 Ypsomed
    • 4.2.11。 Ypsomed 智能設備
    • 4.2.12。 Bigfoot Unity糖尿病管理系統
    • 4.2.13。同伴醫療/美敦力:InPen
    • 4.2.14。胰島素筆的前景
  • 4.3.胰島素泵
    • 4.3.1.胰島素泵
    • 4.3.2.胰島素貼片泵
    • 4.3.3.貼片泵與傳統選項的定價模型
    • 4.3.4.目前可用的胰島素泵
    • 4.3.5。胰島素泵故障
    • 4.3.6.羅氏 Accu-Chek Solo
    • 4.3.7. SOOIL 的 DANA-I
    • 4.3.8.胰島素泵市場
    • 4.3.9.胰島素泵參與者和市場份額
    • 4.3.10。市場:貼片泵與傳統輸液泵
    • 4.3.11。比較胰島素泵和 CGM
    • 4.3.12。胰島素泵技術路線圖
    • 4.3.13。胰島素泵的前景
  • 4.4.連接胰島素泵和 CGM:邁向閉環和人造胰腺
    • 4.4.1.今天:混合閉環系統
    • 4.4.2.混合閉環以匹配進餐時間激增
    • 4.4.3.目標:關閉反饋循環
    • 4.4.4.示例:美敦力的進展
    • 4.4.5。混合閉環系統的合作夥伴生態系統
    • 4.4.6.超速效胰島素:簡介
    • 4.4.7.混合閉環中的超快胰島素案例
    • 4.4.8.實際結果:超快胰島素尚未顯示出對混合閉環的顯著改進
    • 4.4.9。混合閉環系統的比較
    • 4.4.10。美敦力:邁向閉環
    • 4.4.11。美敦力:MiniMed 780G
    • 4.4.12。 Dexcom-Tandem 合作夥伴關係:Control-IQ
    • 4.4.13。絕緣層:Omnipod 5
    • 4.4.14。 CamDiab:CamAPS FX
    • 4.4.15。 Beta仿生學:iLet
    • 4.4.16。潮池:潮池循環
    • 4.4.17。忘記糖尿病項目
    • 4.4.18。關於設備安全性的未回答問題
  • 4.5。替代胰島素技術
    • 4.5.1.無創胰島素輸送方法
    • 4.5.2.各種無創胰島素給藥途徑的比較
    • 4.5.3.吸入胰島素:簡介
    • 4.5.4. MannKind:阿弗雷扎
    • 4.5.5。吸入胰島素面臨市場挑戰
    • 4.5.6。吸入胰島素:展望
    • 4.5.7.口服胰島素給藥
    • 4.5.8.口腔胰島素輸送
    • 4.5.9.經皮胰島素給藥:簡介
    • 4.5.10。研究透皮胰島素給藥的公司
    • 4.5.11。無創胰島素面臨市場採用的幾個障礙
    • 4.5.12。通往無創胰島素輸送的道路以失敗告終
    • 4.5.13。繼續研究無創胰島素輸送的一些原因
    • 4.5.14。葡萄糖反應性胰島素
    • 4.5.15。葡萄糖傳感:Ziylo 方法

5。通過數字健康管理糖尿病

  • 5.1.1.糖尿病管理中數字健康的範圍
  • 5.1.2.糖尿病是數字醫療保健計劃的早期採用者
  • 5.1.3.糖尿病數字健康景觀*
  • 5.1.4.糖尿病管理生態系統
  • 5.1.5。數字健康:法規、合法性和隱私
  • 5.2.移動應用程序中的血糖數據
    • 5.2.1.糖尿病應用
    • 5.2.2.數字健康是由增加的設備連接性驅動的
    • 5.2.3. CGM 與移動應用程序的集成
    • 5.2.4. Dexcom:回顧性和實時 API
    • 5.2.5。 2 級程序利用 Dexcom app-in-app 模塊
    • 5.2.6. WellDoc:藍星
    • 5.2.7.羅氏:SugarView
  • 5.3.生活方式管理應用程序
    • 5.3.1.糖尿病管理:焦點
    • 5.3.2.糖尿病管理的飲食有兩種途徑
    • 5.3.3. Nemaura 醫療:MiBoKo
    • 5.3.4. Fitscript:葡萄糖區
    • 5.3.5。 SNAQ
    • 5.3.6. SNAQ:機器學習技術
  • 5.4.糖尿病管理中的遠程醫療
    • 5.4.1.糖尿病遠程醫療:簡介
    • 5.4.2.糖尿病數字健康計劃的生態系統
    • 5.4.3.遠程醫療計劃通常遵循相同的配方
    • 5.4.4.格洛科
  • 5.5。糖尿病中的數字健康:結論
    • 5.5.1.通過數字健康預防糖尿病前期?
    • 5.5.2.數字健康計劃:2 型糖尿病的證據
    • 5.5.3.數字健康與糖尿病:展望

6。管理糖尿病併發症的技術

  • 6.1.1.管理副作用佔糖尿病總成本的 90%
  • 6.1.2.本報告的範圍
  • 6.2.糖尿病酮症酸中毒
    • 6.2.1.嚴重缺乏胰島素可導致糖尿病酮症酸中毒
    • 6.2.2.通過電化學傳感器監測酮
    • 6.2.3.通過尿液監測酮體
    • 6.2.4.酮體監測:展望
  • 6.3.糖尿病性神經病
    • 6.3.1.糖尿病性神經病變:簡介
    • 6.3.2.糖尿病足潰瘍
    • 6.3.3. Impeto Medical:Sudoscan
    • 6.3.4.糖尿病鞋的基本要求
    • 6.3.5。糖尿病鞋的明智選擇
    • 6.3.6.奧比克斯
    • 6.3.7. Siren Care 丹麥 IVS
    • 6.3.8.偉創力
    • 6.3.9。偉創力
    • 6.3.10。糖尿病足潰瘍:展望
  • 6.4.糖尿病性視網膜病變
    • 6.4.1.糖尿病視網膜病變:簡介
    • 6.4.2.糖尿病視網膜病變在診斷和管理方面取得了進展
    • 6.4.3. Artelus:通過確保圖像質量來檢測 DR
    • 6.4.4.可穿戴助視器
    • 6.4.5。糖尿病視網膜病變:展望

7。糖尿病治療的先進療法

  • 7.1.糖尿病的先進療法:路線圖
  • 7.2.先進療法:簡介
  • 7.3.再生醫學目前很少用於治療糖尿病
  • 7.4. 1 型糖尿病的再生醫學:簡介
  • 7.5。細胞治療設備
  • 7.6.細胞封裝裝置
  • 7.7.細胞治療設備:臨床試驗
  • 7.8。克裡亞療法
  • 7.9。 Diamyd Medical:1型預防醫學
  • 7.10。 2型糖尿病的再生醫學:簡介
  • 7.11。美圖生物製藥
  • 7.12。再生醫學:結論

8。糖尿病中的人工智能

  • 8.1.糖尿病管理中的機器學習
  • 8.2.醫療保健中的人工智能:現有法規
  • 8.3.人工智能可以顯示不同程度的智能
  • 8.4.各種神經網絡及其用於糖尿病管理的用例
  • 8.5。 AI的各種方法概述
  • 8.6.支持人工智能的教練
  • 8.7.人工智能圖像識別
  • 8.8.用於無創葡萄糖傳感的人工智能

9。預測

  • 9.1.預測:介紹
  • 9.2.預測方法:公司糖尿病管理收入
  • 9.3. 2022-2032年糖尿病器械行業市場預測
  • 9.4. 2022-2032年糖尿病器械行業市場預測
  • 9.5。 2010-2032年糖尿病器械行業歷史及預測數據
  • 9.6。 2010-2032 年糖尿病管理設備佔市場總收入的比例
  • 9.7. CGM:2022-2032年年度收入預測
  • 9.8。 CGM:方法論和假設
  • 9.9。 CGM:預測 2 型和前驅糖尿病患者的攝取量
  • 9.10。 CGM:里程碑
  • 9.11。按人口採用比例劃分的 CGM
  • 9.12。 2022-2032 年胰島素泵收入預測
  • 9.13。胰島素泵:預測方法
  • 9.14。 2022-2032年輸液泵收入預測
  • 9.15。 2022-2032 年修補泵收入預測
  • 9.16。 2022-2032年試紙市場預測
  • 9.17。 2022-2032 年血糖儀收入預測
  • 9.18.胰島素筆收入預測 2022-2032

10.公司簡介

  • 10.1.鏈接到 16 個公司簡介
目錄
Product Code: ISBN 9781913899943

Title:
Diabetes Management Technologies 2022-2032: Markets, players, and forecasts
Electrochemical glucose test strips, continuous glucose monitors (CGM) including non-invasive, insulin pumps and pens, closed-loop, artificial pancreas, digital health. Analysis and forecast of diabetes management devices market 2010-2032.

Technologies for diabetes management are expected to reach a total market size of $28.9 bn in 2032.

This report covers the entire landscape for diabetes management devices, including mature, emerging, and future options. We characterise and predict the technological landscape of the industry over the next decade. Strategies of major players in the industry are discussed and analysed. Developments of major milestones, such as the launch of closed-loop systems and non-invasive CGMs, are considered and discussed in our forecasts.

The diabetes management device industry has seen major changes over the past decade. At the centre is the shift from electrochemical test strips towards minimally invasive continuous glucose monitors (CGMs). The billion-dollar test strip industry has been in decline since 2010, while CGMs have only continued to grow. By the year 2032, IDTechEx predicts the test strip industry to make up only 6.7% of the overall diabetes management device market, down from a peak of 63.4% in 2010.

Glucose sensors: past, present, and future

Diabetes patients have historically used disposable test strips for monitoring blood glucose, creating a $7.4 billion industry based on high profit margins on test strips. However, pricing pressures and more stringent reimbursement policies have been driving decline of the test strip industry between 2010 to 2015. In the EU, test strips face additional pressures of increasing CGM reimbursement since 2015. Combined, these factors have seen former leaders in the test strip industry divest their diabetes divisions: Bayer Healthcare sold their diabetes care business to Panasonic in 2016, and in 2017 Johnson and Johnson sold their Lifescan division to Platinum Equity.

On the other hand, the CGM market has seen rapid growth over the last few years. IDTechEx estimates a CAGR of more than 25% between 2010-2021 for the overall CGM industry, driven largely by three major players: Abbott, Medtronic and Dexcom.

CGM market size and shares of key players, 2010-2021.

The growth of CGMs and the decline of test strips is expected to continue as CGMs continue to gain prominence, but there remain several emerging markets test strips are expanding into that will slow their decline. In this report, we discuss the outlook for both the test strip and CGM industries moving forward, providing an account for geographical market penetration for both CGMs and test strips, along with market forecasts for both the test strip and CGM industries over the next 10 years.

While CGMs already offer considerable advantages over test strips, there remains much room for innovation. These devices can still cause discomfort and irritation, and the time lag of CGM measurements is a characteristic flaw of the mechanism they employ.

Digital health: expansion of CGM into type 2 diabetes

Today, the glucose sensor industry serves patients with type 1 diabetes due to the need for strict control over blood glucose levels. However, this is a small subset of all people with diabetes, making up only around 5% of the total. As such, many players are now pushing for device adoption from type 2 and prediabetes populations, as these are large untapped markets. This is being done via increasing integration of glucose sensors with digital health options, with major glucose monitoring players looking to develop partnerships with digital health companies for expanded product offerings.

Innovation within the diabetes management industry has followed a trend of increasing connectivity. This has been seen in the development of smart insulin pens and connected glucometers, among many other examples. While these have all had their parts to play in the recent development of digital health initiatives, CGMs have been a major enabler of digital health.

CGM partnerships with digital health platforms have seen great interest from both ends. CGM data can expand the product offerings of digital health platforms due to this improved data being made available: many diabetes health management apps with CGM pairing offer some form of "diabetes diary" for users to track their blood glucose, with added functionality built on top of this data. On the CGM end, digital health offers the potential for expansion into large untapped type 2 and prediabetes markets. CGM giant Dexcom is the most prominent example of this, partnering with a host of smaller app platforms in addition to an expanded partnership agreement with major telehealth platform Glooko in 2017.

Insulin delivery: progress towards closed-loop

Insulin delivery is a crucial part of diabetes management. Currently, this is mostly done via insulin pens; these devices form the bulk of the insulin delivery market by volume, as their low unit cost make them accessible to consumers.

CGMs have made possible the development of automated ("closed-loop") insulin delivery systems, which could encourage growth of the insulin pump market. This would see major shifts across the insulin delivery industry, with a particularly large impact on insulin pen markets. Within this report, we discuss the development and timelines for such possibilities, along with an analysis and forecast of the impact this would have on the insulin delivery industry over the next decade.

Insulin pump market shares of key players in 2021.

Diabetes management device market analysis and forecasts

The industries discussed above are highly interlinked; developments within one industry cause significant effects on others. IDTechEx have analysed the entire market to produce a cohesive story, tying together developments and future milestones across the diabetes management industry to provide a realistic forecast of each individual market.

While CGMs have been a major focal point of the industry, much notable innovation has occurred across the breadth of the industry. Over the last few years, many new players have entered the diabetes management technology market across multiple industries. This report discusses the market potential of many topics across the entire industry.

This report analyses the technological and competitive landscapes, identifying and reviewing over 100 companies and research institutes ranging from industry leaders to start-ups. It identifies key players in each sector along with partnership ecosystems across several industries.

Key topics discussed in this report:

  • Outlook for the test strip industry moving forward
  • CGM penetration into Asian markets over the short- and medium-term
  • Barriers of entry into CGM markets
  • Outlook for digital health options in diabetes management
  • Trends and outlook within the insulin delivery industry
  • Timeline and impact of closed loop on overall industry
  • Development and outlook of technologies for complication management
  • Developments of advanced therapies for reversal of diabetes

Analyst access from IDTechEx

All report purchases include up to 30 minutes telephone time with an expert analyst who will help you link key findings in the report to the business issues you're addressing. This needs to be used within three months of purchasing the report.

TABLE OF CONTENTS

1. EXECUTIVE SUMMARY

  • 1.1. Executive introduction
  • 1.2. Background: Introduction to diabetes
  • 1.3. Background: The cost of diabetes
  • 1.4. Diabetes management process
  • 1.5. Scope of the report
  • 1.6. Diabetes management device roadmap: Glucose sensors
  • 1.7. Test strips and glucometers: introduction
  • 1.8. Anatomy of a glucose test strip
  • 1.9. Continuous glucose monitors: introduction
  • 1.10. Anatomy of a typical CGM device
  • 1.11. CGM continues to gain momentum
  • 1.12. Non-invasive glucose monitoring
  • 1.13. Non-invasive glucose monitoring: conclusions
  • 1.14. Diabetes management device roadmap: Insulin delivery
  • 1.15. Insulin pens: overview
  • 1.16. Insulin pumps: overview
  • 1.17. Hybrid closed-loop: introduction
  • 1.18. Status of the insulin delivery industry hinges on the development of closed-loop systems
  • 1.19. Alternative insulin delivery methods have yet to gain a foothold
  • 1.20. Digital health is driven by increasing device connectivity
  • 1.21. Digital health is a growing option for diabetes management
  • 1.22. Managing side effects accounts for 90% of the total cost of diabetes
  • 1.23. Outlook for diabetes complication management
  • 1.24. Advanced therapies for diabetes: roadmap
  • 1.25. Advanced therapies: conclusions
  • 1.26. List of 108 companies mentioned in this report
  • 1.27. Diabetes management devices: annual revenue 2010-2021
  • 1.28. Evaluation of the overall diabetes device industry from 2010-2032
  • 1.29. CGM: annual revenue forecast 2022-2032
  • 1.30. Test strip market forecast 2022-2032
  • 1.31. Insulin pumps revenue forecast 2022-2032

2. INTRODUCTION

  • 2.1. Background: Introduction to diabetes
  • 2.2. The prevalence of diabetes
  • 2.3. Background: Diabetes on the rise
  • 2.4. Background: The cost of diabetes
  • 2.5. Type 1 vs Type 2
  • 2.6. Background
  • 2.7. Self-Management Devices
  • 2.8. Diabetes management device roadmap: Summary
  • 2.9. Diabetes management device roadmap: Glucose sensors
  • 2.10. Diabetes management device roadmap: Insulin delivery

3. GLUCOSE SENSORS

  • 3.1.1. History of glucose monitoring
  • 3.1.2. Players in glucose monitoring
  • 3.1.3. Diabetes management device roadmap: Glucose sensors
  • 3.1.4. Key criteria for assessing accuracy
  • 3.2. Test strips and glucometers
    • 3.2.1. Glucose monitoring through test strips and associated readers
    • 3.2.2. Test strips: business model
    • 3.2.3. Anatomy of a glucose test strip
    • 3.2.4. Electrode deposition: screen printing vs sputtering
    • 3.2.5. Lifescan uses multiple manufacturing methods
    • 3.2.6. An introduction to glucose sensing: glucose oxidase
    • 3.2.7. Glucose sensing via GOx: mechanism
    • 3.2.8. Glucose dehydrogenase: introduction
    • 3.2.9. Glucose dehydrogenase: sensing methods
    • 3.2.10. A comparison of GDH and GOx mechanisms
    • 3.2.11. GDH-FAD have potential for development of "third-generation" sensors
    • 3.2.12. Comparison of GDH and GOx in glucose sensing
    • 3.2.13. Overview of several test strips and enzymes used
    • 3.2.14. Roche: Overview
    • 3.2.15. Roche: Accu-Chek Guide
    • 3.2.16. Roche / Glytec: cobas pulse
    • 3.2.17. Abbott Laboratories: Introduction
    • 3.2.18. Abbott: coulometric methods for test strips
    • 3.2.19. EasyMax Diabetes Care
    • 3.2.20. Innovation shifts from test strip development to increasing digitization
    • 3.2.21. Comparing test strip costs with CGM
    • 3.2.22. Test strips: market outlook
  • 3.3. Continuous glucose monitoring (CGM)
    • 3.3.1. Continuous glucose monitors: introduction
    • 3.3.2. Anatomy of a typical CGM device
    • 3.3.3. CGMs are superseding test strips
    • 3.3.4. CGM: Technology
    • 3.3.5. CGM sensor chemistry
    • 3.3.6. CGM technologies: glucose dehydrogenase
    • 3.3.7. CGM miniaturization and "green" diabetes
    • 3.3.8. CGM sensor manufacturing and anatomy
    • 3.3.9. Sensor filament structure
    • 3.3.10. Foreign body responses to CGM devices
    • 3.3.11. Calibration of glucose monitoring devices
    • 3.3.12. Comparison metrics for CGM devices
    • 3.3.13. Example: Accuracy of CGM devices over time
    • 3.3.14. Interference of medication with CGM accuracy
  • 3.4. CGM: Markets and Key Players
    • 3.4.1. CGM: Overview of key players
    • 3.4.2. Abbott Laboratories: CGM business
    • 3.4.3. Abbott: Freestyle® Libre
    • 3.4.4. Abbott: "Wired enzyme"
    • 3.4.5. Abbott: Device and sensor structure
    • 3.4.6. Dexcom: Introduction
    • 3.4.7. Dexcom: CGM products
    • 3.4.8. Dexcom: Sensor structure
    • 3.4.9. Medtronic: Introduction
    • 3.4.10. Medtronic: Diabetes & CGM business
    • 3.4.11. Roche: Patents in CGM
    • 3.4.12. Ascensia, POCTech and Yuwell
    • 3.4.13. Medtrum
    • 3.4.14. Medtrum: Sensing technology
    • 3.4.15. Medtrum: Outlook
    • 3.4.16. AgaMatrix & WaveForm Technologies
    • 3.4.17. Infinovo
    • 3.4.18. Sano
  • 3.5. Implantable glucose sensors
    • 3.5.1. Implantable glucose sensors: Introduction
    • 3.5.2. Key Players in Implantable Glucose Monitoring
    • 3.5.3. Fluorescence-based glucose detection
    • 3.5.4. Senseonics
    • 3.5.5. Senseonics: Financials and Partnerships
    • 3.5.6. GlySens: Eclipse 3
    • 3.5.7. GluSense
  • 3.6. CGM: conclusions
    • 3.6.1. Focus shifts from test strips to CGM
    • 3.6.2. Global CGM reimbursement
    • 3.6.3. CGM markets in Asia
    • 3.6.4. Outlook for smaller test strip companies
    • 3.6.5. CGM reimbursement for type 2 is currently limited
    • 3.6.6. CGM usage in hospitals
  • 3.7. Non-invasive glucose monitoring
    • 3.7.1. Non-invasive glucose monitoring
    • 3.7.2. Assessment of different analytes for glucose monitoring
    • 3.7.3. In Context: FDA requirements
    • 3.7.4. Non-Invasive Blood and ISF
    • 3.7.5. Non-invasive glucose monitoring: approaches
    • 3.7.6. Companies Using Each Technique
    • 3.7.7. Near-Infrared Spectroscopy
    • 3.7.8. Near-Infrared Spectroscopy - Recent Academic Studies
    • 3.7.9. NIR Companies
    • 3.7.10. CNOGA
    • 3.7.11. Mid Infrared Spectroscopy
    • 3.7.12. MIR Companies
    • 3.7.13. DiaMonTech
    • 3.7.14. Terahertz Spectroscopy
    • 3.7.15. Dielectric Spectroscopy
    • 3.7.16. Alertgy
    • 3.7.17. Know Labs
    • 3.7.18. Afon Technology
    • 3.7.19. Zedsen
    • 3.7.20. Zedsen
    • 3.7.21. Raman Spectroscopy
    • 3.7.22. Kaligia Biosciences
    • 3.7.23. Quantum Operation
    • 3.7.24. RSP Systems
    • 3.7.25. Samsung
    • 3.7.26. Optical Rotation
    • 3.7.27. Transdermal Techniques
    • 3.7.28. Reverse Iontophoresis
    • 3.7.29. Reverse Iontophoresis Companies
    • 3.7.30. Nemaura Medical
    • 3.7.31. PKvitality
    • 3.7.32. Cygnus
  • 3.8. Non-invasive glucose monitoring: other fluids
    • 3.8.1. Companies Using Each Technique (Other Fluids)
    • 3.8.2. Measuring glucose in sweat
    • 3.8.3. Measuring glucose in tears
    • 3.8.4. Measuring glucose in saliva
    • 3.8.5. Measuring glucose in breath
    • 3.8.6. Measuring glucose in urine
  • 3.9. Non-invasive glucose monitoring: conclusions
    • 3.9.1. When will non-invasive glucose monitoring be commercialised?
    • 3.9.2. Notable Quotes on Non-Invasive Glucose Monitoring

4. INSULIN DELIVERY

  • 4.1.1. Insulin: introduction
  • 4.1.2. Delivering insulin is a critical part of diabetes management
  • 4.1.3. Comparison of different types of insulin*
  • 4.1.4. Short-acting (bolus) insulin
  • 4.1.5. Long-acting (basal) insulin
  • 4.1.6. Different types of insulin have different use cases
  • 4.1.7. Insulin Delivery Devices
  • 4.1.8. History of insulin delivery methods
  • 4.1.9. Technological roadmap from two separate perspectives
  • 4.2. Insulin pens
    • 4.2.1. Insulin Pens
    • 4.2.2. Smarter insulin delivery informing decisions
    • 4.2.3. Smart pens are driven by a growing CGM market
    • 4.2.4. Partnership ecosystem for smart insulin pens
    • 4.2.5. Overview of commercial smart pen devices*
    • 4.2.6. Novo Nordisk
    • 4.2.7. Novo Nordisk: NovoPen
    • 4.2.8. Eli Lilly
    • 4.2.9. Eli Lilly: Tempo Smart
    • 4.2.10. Ypsomed
    • 4.2.11. Ypsomed smart devices
    • 4.2.12. Bigfoot Unity Diabetes Management System
    • 4.2.13. Companion Medical / Medtronic: InPen
    • 4.2.14. Outlook for insulin pens
  • 4.3. Insulin pumps
    • 4.3.1. Insulin Pumps
    • 4.3.2. Insulin patch pumps
    • 4.3.3. Pricing models for patch pumps vs traditional options
    • 4.3.4. Insulin pumps currently available
    • 4.3.5. Insulin pump breakdown
    • 4.3.6. Accu-Chek Solo by Roche
    • 4.3.7. DANA-I by SOOIL
    • 4.3.8. Insulin pump market
    • 4.3.9. Insulin pump players and market share
    • 4.3.10. Markets: Patch pumps vs traditional infusion pumps
    • 4.3.11. Comparing insulin pumps and CGM
    • 4.3.12. Insulin pump technology roadmap
    • 4.3.13. Outlook for insulin pumps
  • 4.4. Linking insulin pumps and CGM: Towards closed loop and the artificial pancreas
    • 4.4.1. Today: Hybrid closed loop systems
    • 4.4.2. Hybrid closed-loop to match mealtime surge
    • 4.4.3. The objective: Closing the feedback loop
    • 4.4.4. Example: Progress from Medtronic
    • 4.4.5. Partnership ecosystem for hybrid closed-loop systems
    • 4.4.6. Ultra-fast acting insulin: introduction
    • 4.4.7. The case of ultra-fast insulin in hybrid closed -loop
    • 4.4.8. Actual results: ultra-fast insulin have yet to show significant improvements to hybrid closed-loop
    • 4.4.9. Comparison of hybrid closed-loop systems
    • 4.4.10. Medtronic: Towards closed loop
    • 4.4.11. Medtronic: MiniMed 780G
    • 4.4.12. Dexcom-Tandem partnership: Control-IQ
    • 4.4.13. Insulet: Omnipod 5
    • 4.4.14. CamDiab: CamAPS FX
    • 4.4.15. Beta Bionics: iLet
    • 4.4.16. Tidepool: Tidepool Loop
    • 4.4.17. The ForgetDiabetes Project
    • 4.4.18. Unanswered questions about device security
  • 4.5. Alternative insulin technologies
    • 4.5.1. Non-invasive insulin delivery methods
    • 4.5.2. Comparison of various routes for non-invasive insulin delivery
    • 4.5.3. Inhaled insulin: introduction
    • 4.5.4. MannKind: Afrezza
    • 4.5.5. Inhaled insulin faces challenges in the market
    • 4.5.6. Inhaled insulin: outlook
    • 4.5.7. Oral insulin delivery
    • 4.5.8. Buccal insulin delivery
    • 4.5.9. Transdermal insulin delivery: introduction
    • 4.5.10. Companies looking at transdermal insulin delivery
    • 4.5.11. Non-invasive insulins face several barriers to market adoption
    • 4.5.12. The road towards non-invasive insulin delivery is paved with failure
    • 4.5.13. Some reasons why non-invasive insulin delivery continues to be looked at
    • 4.5.14. Glucose-responsive insulin
    • 4.5.15. Glucose sensing: the Ziylo approach

5. DIABETES MANAGEMENT VIA DIGITAL HEALTH

  • 5.1.1. The scope of digital health in diabetes management
  • 5.1.2. Diabetes is an Early Adopter of Digital Healthcare Initiatives
  • 5.1.3. Diabetes digital health landscape*
  • 5.1.4. Diabetes management ecosystem
  • 5.1.5. Digital health: regulations, legality and privacy
  • 5.2. Blood glucose data in mobile apps
    • 5.2.1. Diabetes Apps
    • 5.2.2. Digital health is driven by increasing device connectivity
    • 5.2.3. CGM integration with mobile apps
    • 5.2.4. Dexcom: retrospective and real time APIs
    • 5.2.5. The Level 2 program leverages the Dexcom app-in-app module
    • 5.2.6. WellDoc: BlueStar
    • 5.2.7. Roche: SugarView
  • 5.3. Apps for lifestyle management
    • 5.3.1. Diabetes management: focal points
    • 5.3.2. Diet for diabetes management has two avenues
    • 5.3.3. Nemaura Medical: MiBoKo
    • 5.3.4. Fitscript: GlucoseZone
    • 5.3.5. SNAQ
    • 5.3.6. SNAQ: machine learning techniques
  • 5.4. Telehealth in diabetes management
    • 5.4.1. Telehealth in diabetes: introduction
    • 5.4.2. Ecosystem of a digital health program for diabetes
    • 5.4.3. Telehealth programs often follow the same recipe
    • 5.4.4. Glooko
  • 5.5. Digital health in diabetes: Conclusions
    • 5.5.1. Prediabetes via digital health?
    • 5.5.2. Digital Health Programs: Evidence for Type 2 Diabetes
    • 5.5.3. Digital health and diabetes: outlook

6. TECHNOLOGY FOR MANAGING DIABETES COMPLICATIONS

  • 6.1.1. Managing side effects accounts for 90% of the total cost of diabetes
  • 6.1.2. Scope of this report
  • 6.2. Diabetic Ketoacidosis
    • 6.2.1. A severe lack of insulin can lead to diabetic ketoacidosis
    • 6.2.2. Ketone monitoring via electrochemical sensors
    • 6.2.3. Ketone monitoring via urine
    • 6.2.4. Ketone monitoring: outlook
  • 6.3. Diabetic neuropathy
    • 6.3.1. Diabetic neuropathy: introduction
    • 6.3.2. Diabetic foot ulcers
    • 6.3.3. Impeto Medical: Sudoscan
    • 6.3.4. Basic requirements of a diabetic footwear
    • 6.3.5. Smart options for diabetic footwear
    • 6.3.6. Orpyx
    • 6.3.7. Siren Care Denmark IVS
    • 6.3.8. Flextrapower
    • 6.3.9. Flextrapower
    • 6.3.10. Diabetes foot ulcers: outlook
  • 6.4. Diabetic retinopathy
    • 6.4.1. Diabetic retinopathy: introduction
    • 6.4.2. Diabetic retinopathy has seen developments in diagnosis and management
    • 6.4.3. Artelus: Detecting DR by ensuring image quality
    • 6.4.4. Wearable vision aids
    • 6.4.5. Diabetic retinopathy: outlook

7. ADVANCED THERAPIES FOR DIABETES TREATMENT

  • 7.1. Advanced therapies for diabetes: roadmap
  • 7.2. Advanced therapies: introduction
  • 7.3. Regenerative medicine is currently rarely used to treat diabetes
  • 7.4. Regenerative medicine for type 1 diabetes: introduction
  • 7.5. Cell Therapy Devices
  • 7.6. Cell encapsulation devices
  • 7.7. Cell therapy devices: clinical trials
  • 7.8. Kriya Therapeutics
  • 7.9. Diamyd Medical: preventive medicine for type 1
  • 7.10. Regenerative medicine for type 2 diabetes: introduction
  • 7.11. Mito Biopharma
  • 7.12. Regenerative medicine: conclusion

8. AI IN DIABETES

  • 8.1. Machine learning in diabetes management
  • 8.2. AI in healthcare: Existing regulations
  • 8.3. AI can show varying levels of intelligence
  • 8.4. Various neural networks and use cases of each for diabetes management
  • 8.5. Overview of various methods for AI
  • 8.6. AI-enabled coaching
  • 8.7. AI image recognition
  • 8.8. AI for non-invasive glucose sensing

9. FORECASTS

  • 9.1. Forecast: introduction
  • 9.2. Forecast method: Company revenue in diabetes management
  • 9.3. Diabetes device industry market forecast 2022-2032
  • 9.4. Diabetes device industry market forecast 2022-2032
  • 9.5. Diabetes device industry historic and forecast data 2010-2032
  • 9.6. Diabetes management devices by proportion of total market revenue 2010-2032
  • 9.7. CGM: annual revenue forecast 2022-2032
  • 9.8. CGM: methodology and assumptions
  • 9.9. CGM: forecasted uptake by type 2 and prediabetes
  • 9.10. CGM: Milestones
  • 9.11. CGMs by population adoption proportion
  • 9.12. Insulin pumps revenue forecast 2022-2032
  • 9.13. Insulin pumps: forecast methodology
  • 9.14. Infusion pumps revenue forecast 2022-2032
  • 9.15. Patch pumps revenue forecast 2022-2032
  • 9.16. Test strip market forecast 2022-2032
  • 9.17. Glucometers revenue forecast 2022-2032
  • 9.18. Insulin pens revenue forecast 2022-2032

10. COMPANY PROFILES

  • 10.1. Links to 16 company profiles